A study to assess safety, pharmacokinetics Anti-Drug Antibody and anti-RSV antibody after 2 doses of nirsevimab

Trial Identifier: D5290C00009
Sponsor: AstraZeneca
Collaborator:
IQVIA
Start Date: July 2023
Primary Completion Date: July 2025
Study Completion Date: July 2025
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
JP Bunkyo-ku, JP, 113-8519
JP Fuchu-shi, JP, 183-8561
JP Fukuoka-shi, JP, 813-0017
JP Kitakyusyu-shi, JP, 806-8501
JP Koto-ku, JP, 135-8577
JP Kurume-shi, JP, 830-0011
JP Nagasaki-shi, JP, 852-8501
JP Saitama-shi, JP, 336-8522
JP Yokohama-shi, JP, 232 8555